J. Craig Venter Institute

What J. Craig Venter Institute does

J. Craig Venter Institute (JCVI) is a private 501(c)(3) nonprofit genomics and synthetic biology research institute headquartered in La Jolla, California with a second research facility in Rockville, Maryland. Founded through the 2004-2006 consolidation of the Center for the Advancement of Genomics (TCAG), the Institute for Biological Energy Alternatives (IBEA), and the J. Craig Venter Joint Technology Center, the institute carries forward the scientific legacy of J. Craig Venter, including the first free-living organism genome sequenced via whole-genome shotgun (1995), a draft human genome (2000), the first self-replicating synthetic bacterial cell (JCVI-syn1.0, 2010), and the first minimal synthetic cell with only 473 genes (JCVI-syn3.0, 2016). The institute employs approximately 120 scientists and staff organized across five research programs: Human Health, Environmental Sustainability, Synthetic Biology, Technology & Tools, and Policy Research.

JCVI's core technology stack spans whole-genome shotgun sequencing, synthetic genome construction and cell boot-up, multi-omics bioprospecting, and computational whole-cell modeling — including a 4D simulation of JCVI-syn3A published in Cell in 2026. Notable research outputs include the Global Ocean Sampling Expedition (millions of new genes), the ViPR open bioinformatics database, and the CIRCLE Global Center for waste-stream valorization and bioeconomy research. The institute serves the global scientific research community, federal funders (primarily NIH/PHS, NSF, DOE), and international research consortium partners.

JCVI's revenue model is grant-driven rather than commercial. The institute is the largest recipient of research funding from NIH and other Public Health Service agencies, supplemented by NSF and DOE grants, philanthropic donations (Genomic Frontier Fund), sponsored research agreements, and international consortium funding (e.g., CIRCLE with partners in Canada, Korea, and the UK). JCVI also operates commercial-adjacent vehicles including the 2026 spinout Diploid Genomics, Inc. (DGI) and historical minority holdings in Synthetic Genomics (now Viridos), Human Longevity, and SGI DNA (now Telesis Bio). Following founder J. Craig Venter's death in April 2026, leadership transitioned to President Anders Dale.

Name

J. Craig Venter Institute

Legal name

J. Craig Venter Institute

Website

https://jcvi.org

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

101–250 employees

Short description

JCVI is a 501(c)(3) nonprofit genomics and synthetic biology research institute with ~120 staff in La Jolla and Rockville, conducting federally funded research in human health, synthetic biology, environmental sustainability, and bioeconomy for the global scientific community.

Ownership category

akta.pro rank

Product category

Genomics Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA)

akta.pro secondary industries

Transcriptomics & Gene Expression Profiling Services (HLAGANAE), Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM)

Keywords

• Genomics research
• Synthetic biology
• Bioinformatics analysis
• DNA sequencing services
• Metagenomics research

Headquarters

HQ city

Rockville

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Federal Research Grants: Primary revenue source from federal agencies including the National Institutes of Health (NIH) and other Public Health Service (PHS) agencies. JCVI is the largest research funding recipient from NIH and PHS agencies. Funding also comes from NSF, DOE, and other federal sources.
2. Philanthropy and Donations: The Genomic Frontier Fund provides unrestricted philanthropic support to JCVI programs and operating expenses. Donations are directed to areas of highest need including early stage research.
3. Sponsored Research Agreements: Fee-for-service research collaborations with academic institutions, government agencies, and industry partners. Includes subcontracts from other research institutions.
4. International Consortium Funding: Joint funding from international partners including NSF, Canadian agencies (NSERC, SSHRC), Korea's National Research Foundation, and UK Research and Innovation for the CIRCLE Global Center.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

J. Craig Venter Institute (JCVI) is a nonprofit research organization that conducts genomics, synthetic biology, and bioinformatics research across four core programs: Human Health, Environmental Sustainability, Synthetic Biology, and Technology & Tools. JCVI delivers sponsored research services, develops synthetic genomes and minimal cells, performs high-throughput DNA sequencing, and operates open-access bioinformatics resources such as the Virus Pathogen Resource (ViPR) database. Its work is supported by federal grants (primarily NIH and NSF), philanthropy, and research collaborations with academic, government, and industry partners.

Product overview

The J. Craig Venter Institute is a not-for-profit research institute (501(c)(3)) with approximately 120 scientists and staff in La Jolla, California and Rockville, Maryland. JCVI does not offer a commercial product in the traditional SaaS sense; rather, it conducts genomics research across four core areas: Human Health (including cancer genomics and microbiome studies), Environmental Sustainability (including plastic degradation and bioeconomy research through CIRCLE), Synthetic Biology (including minimal cell development and genome synthesis), and Technology & Tools (high-throughput sequencing and bioinformatics). Key research outputs include the JCVI-syn3.0 minimal synthetic cell (473 genes, the smallest self-replicating organism) and JCVI-syn1.0 (first synthetic self-replicating cell). JCVI also maintains policy research programs on biosecurity and bioethics. The institute collaborates with academic and industry partners including the NSF Global Centers program, NIH, and international funding agencies.

Differentiator

Problem solved

Functional benefit

Brands

• CIRCLE: Center for Innovative Recycling and Circular Economy - NSF Global Center focused on waste-stream valorization and bioeconomy research
• Genomic Frontier Fund

Products and services

• Human Health Research Program Research program advancing understanding of human health and disease to enhance lives beyond managing health risks, including cancer genomics, human genome resequencing and analysis, and microbiome studies.
• Environmental Sustainability Research Program Research program that uses DNA sequencing, analysis, and synthetic biology techniques to harness microbes for environmental applications including plastic degradation and sustainable agriculture.
• Synthetic Biology Research Program Research program creating organisms with synthetic genomes, including minimal cells and genome design, construction, and boot-up capabilities.
• Center for Innovative Recycling and Circular Economy (CIRCLE) NSF Global Center focused on advancing bioeconomy research through waste-stream valorization, developing scalable solutions for plastic upcycling, C1 gas conversion, and biogenic waste valorization using multi-omics bioprospecting, computational protein engineering, and techno-economic analysis.
• Technology & Tools Research Program

Quantifiable outcome

• First draft human genome sequence completed in 2000, revolutionizing biomedical science
• +4 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature7 records

Partnerships

Ten partnerships are on record, tiered key and strategic.

• University of Illinois Urbana-ChampaignkeyStrategic or Co-development Partner · 23 January 2026Research collaborator on 4D whole-cell model of minimal bacterium JCVI-syn3A, developing computational simulation of living cell.
• Harvard Medical SchoolkeyStrategic or Co-development Partner · 23 January 2026Research collaborator on 4D whole-cell computational modeling project alongside JCVI and University of Illinois.
• PacBiostrategicTechnology or Integration · 22 January 2026Sequencing technology provider for new startup Diploid Genomics, Inc. (DGI) - providing long-read sequencing technology for AI-driven genomics analytics.
• Oxford NanoporestrategicTechnology or Integration · 22 January 2026Sequencing technology provider for Diploid Genomics, Inc. (DGI) - providing nanopore sequencing technology for diagnostic insights.
• Kansas State UniversitykeyStrategic or Co-development Partner · 2 October 2024Academic partner in CIRCLE consortium with researcher Jikai Zhao, PhD contributing to waste valorization research.
• North Carolina A&T State UniversitykeyStrategic or Co-development Partner · 2 October 2024Academic partner in CIRCLE consortium with researcher Reza Zadegan, PhD contributing to bioeconomy research.
• NC State UniversitykeyStrategic or Co-development Partner · 2 October 2024Academic partner in CIRCLE consortium with researchers Sunkyu Park, PhD and Kai Lan, PhD contributing to synthetic biology and waste valorization.
• Keck Graduate InstitutekeyStrategic or Co-development Partner · 2 October 2024Academic partner in CIRCLE consortium with researchers Saurav Datta, PhD and Gargi Ghosh, PhD contributing to bioprocess engineering.
• Columbia UniversitykeyStrategic or Co-development Partner · 2 October 2024Academic partner in CIRCLE consortium with researcher Anum Glasgow, PhD contributing to computational biology approaches.
• Synthetic Genomics, Inc. (SGI)keyStrategic or Co-development PartnerClose collaborator and spinout company focused on synthetic biology tools and services. Funded work on first synthetic cell and minimal cell research.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Twist Bioscience: Commercial synthetic biology and DNA synthesis company. Comparable in synthetic biology and DNA technologies but operates as a public commercial entity focused on DNA synthesis rather than fundamental research.
• Ginkgo Bioworks: Public synthetic biology company operating commercial cell engineering platforms. Comparable in synthetic biology capability but operates as a for-profit enterprise that has commercialized many of the research areas JCVI pioneered.

Broad incumbents

• Wellcome Sanger Institute: Large-scale genomic sequencing and bioinformatics research institute in the UK, comparable as a globally leading genomics R&D organization with similar large-scale sequencing and bioinformatics capabilities, though broader in scope.
• Allen Institute: Nonprofit research organization founded with philanthropic support conducting large-scale science projects. Comparable in nonprofit R&D model and large-scale data generation, though focused on brain science and cell biology rather than synthetic biology.

Direct peers

• Broad Institute: Joint research institute of MIT and Harvard conducting large-scale genomic, synthetic biology, and biomedical research. Directly comparable as a major nonprofit genomics R&D organization with similar funding model (NIH, philanthropy) and overlapping research areas.
• Salk Institute for Biological Studies: Nonprofit biological research institute in La Jolla, CA with comparable headcount (~1,000+ scientists) and federal-grant-funded research model. Overlap in genomics, synthetic biology, and molecular biology research programs in the same geographic cluster.
• Scripps Research: Nonprofit biomedical research organization in La Jolla with similar scale and federal grant reliance. Comparable as a leading nonprofit research institute with overlapping work in chemistry, biology, and translational science.
• Whitehead Institute for Biomedical Research: Nonprofit biomedical research institute affiliated with MIT with comparable headcount and mission in fundamental biological research, including genomics and synthetic biology. Similar funding profile and research model.
• New York Genome Center: Nonprofit academic genomics research institute in New York conducting large-scale sequencing and multi-omics research. Comparable in nonprofit genomics R&D model, federal-grant funding, and collaborative research structure.
• Baylor College of Medicine Human Genome Sequencing Center: Major NIH-funded large-scale genome sequencing and genomics research center. Directly comparable as a nonprofit/academic genomics sequencing center with similar funding model and research output areas.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/JCVenterInst
• LinkedInlinkedin.com/company/j-craig-venter-institute

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries7 records

Funding overview

Funding rounds5 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about J. Craig Venter Institute